Overall, prasugrel may be superior to the approved dose of the older drug, clopidogrel (Plavix), in many cases. But more doctors have been using an initial, higher-than-standard dose of ...

Dr. Hutter: Hello. Welcome to Conversations with Experts; I'm Dolph Hutter. Today we're talking about "Clopidogrel Resistance: Its Significance and Management." With me is Dr. Gilles Montalescot ...

Clopidogrel is an anti-platelet agent, that is, a drug that inhibits the ability of platelets to clump together as part of a blood clot. The serum concentration of the active metabolites of ...

FDA-approved indications currently recommend that patients who undergo percutaneous intervention with drug-eluting stents (DESs) should be treated with clopidogrel for 3–6 months; however ...

it is not inconceivable that some doctors who were more willing to use the antiplatelet drug with higher cost (clopidogrel) were also more inclined to prescribe statin drugs. Finally, our cohort ...

1,2 Failure to achieve sufficient levels of platelet inhibition with either drug have been correlated with undesirable cardiovascular outcomes. 3,4 Clopidogrel resistance is not an uncommon phenomena.

Operating on patients with clopidogrel poses a challenge because of the risk of bleeding and the difficulty deciding the optimal timing of surgery. The aim of this systematic review is to examine ...

barrowneuro.org Background Omeprazole is a common proton pump inhibitor that interferes with the hepatic activation of clopidogrel and potentially reduces ... outcomes in patients treated with ...

MEDLINE e38. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention ...

Gómez-Mantilla, J.D.; Selzer, D.; Lehr, T. Physiologically based pharmacokinetic (PBPK) modeling of clopidogrel and its four relevant metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 drug-drug-gene ...